Nanoparticles loaded with chemotherapeutic antitumoral drug

A method for reducing, in a cancer patient, the occurrence or severity of macroscopic lung injuries induced by nanoparticles that comprise:

• at least one chemotherapeutic antitumoral agent that is doxorubicin or a pharmaceutically acceptable salt thereof,
• at least one poly(alkylcyanoacrylate), and
• at least one cyclodextrin,
• the method comprising administering the nanoparticles to the cancer patient by intravenous infusion for about 6 hours;
• wherein the macroscopic lung injuries induced by the nanoparticles occur two or more days after infusion;
• wherein the dosage of doxorubicin or pharmaceutically acceptable salt thereof administered by said intravenous infusion is from about 20 to about 30 mg/m2;
• wherein the cancer patient has an advanced hepatocellular carcinoma after failure or intolerance to sorafenib.

A method for reducing, in a cancer patient, the mortality associated with macroscopic lung injuries induced by nanoparticles that comprise:

• at least one chemotherapeutic antitumoral agent that is doxorubicin or a pharmaceutically acceptable salt thereof,
• at least one poly(alkylcyanoacrylate), and
• at least one cyclodextrin,
• the method comprising administering the nanoparticles to the cancer patient by intravenous infusion for at least 2 hours;
• wherein the macroscopic lung injuries induced by the nanoparticles occurs two or more days after infusion;
• wherein the dosage of doxorubicin or pharmaceutically acceptable salt thereof administered by said intravenous infusion is from about 10 to about 30 mg/m2.

A method for reducing, in a cancer patient, the occurrence of fatal respiratory distress induced by nanoparticles that comprise:

• at least one chemotherapeutic antitumoral agent that is doxorubicin or a pharmaceutically acceptable salt thereof,
• at least one poly(alkylcyanoacrylate), and
• at least one cyclodextrin,
• the method comprising administering the nanoparticles to the cancer patient by intravenous infusion for at least 2 hours;
• wherein the fatal respiratory distress induced by the nanoparticles occurs two or more days after infusion;
• wherein the dosage of doxorubicin or pharmaceutically acceptable salt thereof administered by said intravenous infusion is from about 10 to about 30 mg/m2.